Sanofi has extended its master services agreement with Swedish drug discovery firm Beactica to characterise the interactions between new therapeutics and their target proteins.

The three-year extension agreement covers the legal terms associated with the collaboration, which has been ongoing since 2015.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the partnership, Beactica scientists have worked with Sanofi for the analysis of the kinetics that occurs when insulin analogues interact with their two binding sites present on the full-length insulin receptor.

Findings from this alliance are said to have contributed towards the regulatory approval of Sanofi’s rapid-acting insulin biosimilar called Insulin lispro Sanofi.

“We look forward to continuing our fruitful collaboration with Sanofi.”

Beactica CEO Dr Per Källblad said: “We are pleased to extend our agreement with Sanofi and look forward to continuing our fruitful collaboration.

“It is very rewarding to see tangible evidence on how Beactica’s expertise and capabilities contribute towards products that increase the quality of life for patients living with compromised health conditions.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Founded in 2006, Beactica uses in-house methodologies to investigate molecule interactions for developing new therapeutics.

The firm also conducts drug discovery programmes to address areas with unmet medical need and allows collaborations for fragment-based lead generation using its discovery platform.

Beactica have established partnerships with numerous pharmaceutical and biotech companies, including Boehringer Ingelheim and Johnson & Johnson’s subsidiary Janssen R&D.